DDInter93 DDInter1376
Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Anagrelide {u} (Compound) treats {v} (Disease) hematologic cancer
Anagrelide {u} (Compound) binds {v} (Gene) CYP1A2
Anagrelide {u} (Compound) upregulates {v} (Gene) HMG20B
Anagrelide {u} (Compound) is included by {v} (Pharmacologic Class) Phosphodiesterase 3 Inhibitors
Anagrelide {u} (Compound) downregulates {v} (Gene) TM9SF2
Anagrelide {u} (Compound) causes {v} (Side Effect) Distress gastrointestinal
Anagrelide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Anagrelide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carvedilol
Anagrelide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Milrinone
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Vorapaxar
Anagrelide (Compound) treats hematologic cancer (Disease)
Anagrelide (Compound) binds CYP1A2 (Gene)
Anagrelide (Compound) upregulates HMG20B (Gene)
Anagrelide (Compound) is included by Phosphodiesterase 3 Inhibitors (Pharmacologic Class)
Anagrelide (Compound) downregulates TM9SF2 (Gene)
Anagrelide (Compound) causes Distress gastrointestinal (Side Effect)
Anagrelide may cause a minor interaction that can limit clinical effects when taken with Capsicum
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Milrinone
Anagrelide may lead to a major life threatening interaction when taken with Vorapaxar